Search / Trial NCT06230744

A Novel Intervention for Weight Loss in Young Adults

Launched by UNIVERSITY OF CHICAGO · Jan 19, 2024

Trial Information

Current as of January 08, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help young adults lose weight by combining a behavioral intervention with technology, like smartphone apps. The goal is to see if this approach can make a real difference in helping people who are overweight or obese (with a body mass index between 25.5 and 34.9) improve their health. The trial is looking for participants aged 18 to 40 who have been stable in their weight (not losing or gaining more than 25 pounds) for the past three months and own a smartphone.

Participants in the trial can expect to engage in activities that promote healthy weight loss while using a study app to support their journey. However, there are specific eligibility criteria, and those with certain health conditions (like diabetes, heart disease, or severe sleep issues) or who are currently on weight loss diets may not qualify. This trial aims to find new strategies to combat weight-related health issues, which are a growing concern for many young adults today.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Overweight or obese (BMI 25.5- 34.9 kg/m2) men and women
  • Ages 18 to 40 years
  • Weight stable (no change \>25 lbs in the past 3 months)
  • Owns a smartphone and willing to install the study app
  • Exclusion Criteria:
  • Presence of obstructive sleep apnea or history of any other sleep disorder.
  • Irregular menses, menopausal symptoms or post-menopausal, currently pregnant, trying to get pregnant or nursing
  • Regular travel across time zones
  • Subjects who are currently following a weight loss regimen or any other special diet or exercise programs
  • Increased fractional lean body mass (e.g., athletes)
  • Unable to walk, using an assistive device for mobility, or any contraindications to exercise
  • Diabetes
  • Claustrophobia
  • Excessive alcohol (\>2 drinks/day) or caffeine (\>300mg/day) intake, regular nicotine use, substance abuse.
  • Abnormal findings on screening blood testing.
  • Participants taking any prescription, over-the-counter drugs/supplements that can affect sleep or weight.
  • Major psychiatric or any eating disorder, and any acute or chronic medical condition that increase the risk of interventions (e.g., heart disease)
  • Any underlying disease likely to limit life span and/or increase risk of interventions including cardiovascular disease (e.g. unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, NYHA Class\>2), pulmonary disease with dependence on oxygen or daily use of bronchodilators, cancer requiring treatment in the past 5 years unless the prognosis is considered good, active or chronic infection, thyroid disease and other endocrine disorders (e.g. Cushing syndrome, acromegaly), hepatitis or other chronic gastrointestinal disease (pancreatitis, inflammatory bowel disease), renal disease, significant anemia, recent surgery or significant abdominal surgery, major psychiatric or any eating disorder, acute coronary syndrome or stroke in the past 6 months

Trial Officials

Esra Tasali, MD

Principal Investigator

University of Chicago

About University Of Chicago

The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.

Locations

Chicago, Illinois, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0